Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label everolimus monotherapy in previously treated advanced NSCLC
2004-003018-41Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoint: Objective tumor response rate. Started Jun 2006; status: completed.
02
Drugs
everolimus
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-003018-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003018-41.